about
Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesExercise benefits brain function: the monoamine connectionLong-Term Potentiation at CA3-CA1 Hippocampal Synapses with Special Emphasis on Aging, Disease, and Stress.Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonismOscillating Magnet Array-Based Nanomagnetic Gene Transfection: A Valuable Tool for Molecular Neurobiology Studies.Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease.The role of microglia in synaptic stripping and synaptic degeneration: a revised perspective.Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.Synaptic protein alterations in Parkinson's disease.Synaptic plasticity in neurodegenerative diseases evaluated and modulated by in vivo neurophysiological techniques.New synaptic and molecular targets for neuroprotection in Parkinson's disease.Developmental neuroplasticity and the origin of neurodegenerative diseases.Motor cortical plasticity in Parkinson's disease.The pathomechanisms underlying Parkinson's disease.Elucidating the role of the pLG72 R30K substitution in schizophrenia susceptibility.Regulating levels of the neuromodulator d-serine in human brain: structural insight into pLG72 and d-amino acid oxidase interaction.The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains.Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.A Special Extract of Bacopa monnieri (CDRI-08) Restores Learning and Memory by Upregulating Expression of the NMDA Receptor Subunit GluN2B in the Brain of Scopolamine-Induced Amnesic Mice.LRRK2 in Transcription and Translation Regulation: Relevance for Parkinson's Disease.Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions.Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: implication for Parkinson's disease.Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia.Differential expression of synaptic proteins in unilateral 6-OHDA lesioned rat model-A comparative proteomics approach.Tetramethylpyrazine alleviated cytokine synthesis and dopamine deficit and improved motor dysfunction in the mice model of Parkinson's disease.Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.Effects of L-Dopa and pramipexole on plasticity induced by QPS in human motor cortex.GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease.Exercise-Induced Fatigue Impairs Bidirectional Corticostriatal Synaptic Plasticity.
P2860
Q28072353-18F24125-090E-4087-83A7-98651A5141F5Q33772106-A17B7AE0-5ECB-4B67-B0CB-663F650534A1Q35007766-BA3692F0-9093-4942-9A09-408508A8A902Q35028568-52CB1F4B-A79F-4037-A943-91E4CE109790Q36321329-7B637B20-885A-4B93-B28E-5B984953CFE9Q36737512-6A394829-58D5-4EF2-A743-5AE540C5B14EQ37802202-4686B36C-0A32-46C8-B2FE-0F19C201AC19Q37955871-2842B12E-D391-4DA5-BFA2-715893A21B2CQ37972089-7F06A5A3-5654-4852-A84E-17540D1CDC25Q38028376-017CB148-3660-4D5B-A5C7-732CD6BAC4AFQ38038559-2A7754A6-67A5-42EC-A1A6-5720D1BF580DQ38109214-832280D6-2B77-4B21-A455-AD054BEE6006Q38136650-7DAB6E41-4BAC-4F99-8D79-30B4BC10C4C7Q38182660-61D4CD97-4832-4908-B71C-E197020283DBQ38717701-7F7306ED-600E-4B96-B3AF-65ECD67BCF65Q39613722-A45A2CBB-B6C4-4750-9282-34EF35474289Q40261770-6E4C7CC8-09B0-4C7F-A59E-BC4E863FCD07Q40313187-0CB332A8-9A18-4038-9C94-AB9DA2BCC4B6Q40493017-FE2D761C-5AE2-4214-A633-B07E79507A96Q41009946-1E865E27-51F0-435B-8A0D-B0181EE094E1Q41903612-07C89663-2761-403B-981A-15DEE9C1C5A5Q42023708-78DF40D7-DDF7-46A9-9E00-E238450E8347Q42177230-9C5C05F6-495F-411E-A139-6C6A7D92B902Q42459197-0BEF350F-7F2A-484C-991F-AC69937590F2Q42462211-5F45C765-413B-4EA1-A64E-87B70626C88FQ43120924-771D0FC5-5F0C-4FCB-B384-FAD87E6B5A79Q47920457-C04009EC-00D1-412D-AF91-1B196C599625Q48119291-08A999A1-74DA-4E32-9B4E-77014A8874D3Q48362193-1ACD907A-6BBD-49AF-BFA4-52B25C89BDDDQ49193847-688E1000-1C76-469B-9563-837A8058CE81
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Synaptic dysfunction in Parkinson's disease.
@en
type
label
Synaptic dysfunction in Parkinson's disease.
@en
prefLabel
Synaptic dysfunction in Parkinson's disease.
@en
P50
P356
P1476
Synaptic dysfunction in Parkinson's disease
@en
P2093
Paolo Calabresi
Vincenza Bagetta
P304
P356
10.1042/BST0380493
P577
2010-04-01T00:00:00Z